Teva Pharma (TEVA) Cut to Junk by S&P; to BB/Stable from BBB-/Watch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Teva Pharma (TEVA) PT Lowered to $23 at Goldman Sachs; Remains Bullish as Expectations Reset
February 9, 2018 8:52 AM ESTGoldman Sachs lowered its price target on Teva Pharma (NYSE: TEVA) to $23.00 (from $25.00) while maintaining a Buy rating following the company's 4Q earnings and meetings with management.
While 2018 guidance came in lower than expected, analyst Jami Rubin believes it helps reset investor expectations and,... More
Teva Pharma (TEVA) PT Lowered to $16.50 at Wells Fargo
February 9, 2018 8:05 AM ESTWells Fargo lowered its price target on Teva Pharma (NYSE: TEVA) to $16.50 (from $17.00) while maintaining an Underperform rating.
"We believe the conference call went poorly and reinforced worries about the weak 2018 guidance," analyst David Maris commented.
Lowers FY 2018 EPS to $2.43, which compares to Tevas guidance of $2.25-2.50.
... More